Piramal Pharma Solutions Partners with IntoCell
Piramal Pharma Solutions has partnered with IntoCell to expand its bioconjugates offering and support innovation in the field.
The partnership aims to explore potential collaboration opportunities in ADC development, with IntoCell licensing its proprietary drug-linker technologies to Piramal's clients.
Piramal Pharma Solutions has signed a Memorandum of Understanding (MOU) with IntoCell Inc., a leading Korean biotechnology company specializing in innovative antibody-drug conjugate (ADC) linker and payload platform technologies.
Author's summary: Piramal Pharma Solutions partners with IntoCell to boost bioconjugates.
More News
- From MRI to Ozempic: breakthroughs that show why fundamental research must be protected
- Will ARC Raiders Survive? A Deep Dive Into Its Future | Invision Game Community
- CBP Officers Intercept Nearly Half a Million Dollars Worth of Meth at Andrade Port of Entry - HSToday
- Austin Reaves cracks viral joke after buzzer-beater lifts Lakers to win
- Trump Is Rewriting History to Justify His Sketchy Pardon of a Crypto King
- Mali annuls 90-plus mining exploration permits amid legal changes
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- John Malone steps down as Liberty Media chairman
- Yankees Icon Derek Jeter Takes A Dig At Dodgers' COVID Ring
- Stanley Gibbons Baldwin's Auction Highlights Preview: October 31, 2025